Latest Certolizumab pegol Stories
ATLANTA, May 16, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia(®) (certolizumab
SAN FRANCISCO, Oct.
Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA,
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With No Systemic Exposure GHENT, Belgium, Oct.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension
SAN FRANCISCO, Jan.
- A young chicken: also used as a pet name for children.